Evidence map›Paper›PMID 39913124›Full record

ArticleTranslational vision science & technology2025

Deep Learning Approaches to Predict Geographic Atrophy Progression Using Three-Dimensional OCT Imaging.

Kenta Yoshida, Neha Anegondi, Adam Pely, Miao Zhang, Frederic Debraine, Karthik Ramesh, Verena Steffen, Simon S Gao, Catherine Cukras, Christina Rabe and 5 more

3 registry-linked trialsAbstract read
In one paragraph

Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02247479 phase3terminatednot on this map

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

TypeinterventionalSponsorHoffmann-La RocheRan2014 to 2018Enrolled906ConditionsGeographic AtrophyArmsLampalizumab, Sham
NCT02247531 phase3terminatednot on this map

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

TypeinterventionalSponsorHoffmann-La RocheRan2014 to 2018Enrolled975ConditionsGeographic AtrophyArmsLampalizumab, Sham Comparator
NCT02479386 terminatednot on this map

A Multicenter, Prospective Epidemiologic Study of The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration

TypeobservationalSponsorHoffmann-La RocheRan2015 to 2018Enrolled296ConditionsGeographic AtrophyArmsNo intervention
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kenta YoshidaClinical Pharmacology, Genentech, Inc., South San Francisco, CA, USA.
Neha AnegondiClinical Imaging Group, Genentech, Inc., South San Francisco, CA, USA.
Adam PelygRED Computational Science, Genentech, Inc., South San Francisco, CA, USA.
Miao ZhanggRED Computational Science, Genentech, Inc., South San Francisco, CA, USA.
Frederic DebraineProduct Development Ophthalmology, Genentech, Inc., South San Francisco, CA, USA.
Karthik RameshProduct Development Ophthalmology, Genentech, Inc., South San Francisco, CA, USA.
Verena SteffenProduct Development Data Science, Genentech, Inc., South San Francisco, CA, USA.
Simon S GaoClinical Imaging Group, Genentech, Inc., South San Francisco, CA, USA.
Catherine CukrasDepartment of Ophthalmology, Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Christina RabeProduct Development Data Science, Genentech, Inc., South San Francisco, CA, USA.
Daniela FerraraProduct Development Ophthalmology, Genentech, Inc., South San Francisco, CA, USA.
Richard F SpaideVitreous Retina Macula Consultants of New York, New York, NY, USA.
SriniVas R SaddaDoheny Eye Institute, Los Angeles, California; Department of Ophthalmology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.
Frank G HolzDepartment of Ophthalmology and GRADE Reading Center, University of Bonn, Bonn, Germany.
Qi YangProduct Development Ophthalmology, Genentech, Inc., South San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate the performance of various approaches of processing three-dimensional (3D) optical coherence tomography (OCT) images for deep learning models in predicting area and future growth rate of geographic atrophy (GA) lesions caused by age-related macular degeneration (AMD). Methods: The study used OCT volumes of GA patients/eyes from the lampalizumab clinical trials (NCT02247479, NCT02247531, NCT02479386); 1219 and 442 study eyes for model development and holdout performance evaluation, respectively. Four approaches were evaluated: (1) en-face intensity maps; (2) SLIVER-net; (3) a 3D convolutional neural network (CNN); and (4) en-face layer thickness and between-layer intensity maps from a segmentation model. The processed OCT images and maps served as input for CNN models to predict baseline GA lesion area size and annualized growth rate. Results: For the holdout dataset, the Pearson correlation coefficient squared (r2) in the GA growth rate prediction was comparable for all the evaluated approaches (0.33∼0.35). In baseline lesion size prediction, prediction performance was comparable (0.9∼0.91) except for the SLIVER-net (0.83). Prediction performance with only the thickness map of the ellipsoid zone (EZ) or retinal pigment epithelium (RPE) layer individually was inferior to using both. Addition of other layer thickness or intensity maps did not improve the prediction performance. Conclusions: All explored approaches had comparable performance, which might have reached a plateau to predict GA growth rate. EZ and RPE layers appear to contain the majority of information related to the prediction. Translational Relevance: Our study provides important insights on the utility of 3D OCT images for GA disease progression predictions.

Indexed as

Deep LearningGeographic AtrophyImaging, Three-DimensionalTomography, Optical CoherenceAgedClinical Trials as TopicDisease ProgressionFemaleHumansMacular DegenerationMaleNeural Networks, Computer

Identifiers

PMID39913124
PMCPMC11806428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.